Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Prostate Cancer Metastatic × Hydrocortisone × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 9 Leukemia, Biphenotypic, Acute 5 Prostatic Neoplasms 3 Burkitt Lymphoma 3 Recurrence 1 Prostate Cancer Metastatic 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Pancreatitis 1 Pancreatic Intraductal Neoplasms 1 Neoplasm Metastasis 1 Myelodysplastic Syndromes 1 Leukemia, Myelomonocytic, Juvenile 1 Leukemia, Myeloid, Acute 1 Leukemia 1 Hematopoietic and Lymphatic System Neoplasm 1 Fistula 1 Duodenal Neoplasms 1 Drug-Related Side Effects and Adverse Reactions 1

Interventions

fludrocortisone acetate 1 enzalutamide 1 Radiotherapy, Image-Guided 1 Radiotherapy 1 Radiosurgery 1 Prednisone 1 Hydrocortisone 1 Gonadotropin-Releasing Hormone 1 Dexamethasone 1 Androgen Antagonists 1 Abiraterone Acetate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06136624 2026-03-11

OMAHA-003

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡